STAAR Surgical - STAA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $47.13
  • Forecasted Upside: 10.86%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$42.51
▼ -0.29 (-0.68%)

This chart shows the closing price for STAA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New STAAR Surgical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STAA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STAA

Analyst Price Target is $47.13
▲ +10.86% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for STAAR Surgical in the last 3 months. The average price target is $47.13, with a high forecast of $57.00 and a low forecast of $35.00. The average price target represents a 10.86% upside from the last price of $42.51.

This chart shows the closing price for STAA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 polled investment analysts is to hold stock in STAAR Surgical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2024Needham & Company LLCReiterated RatingHoldLow
5/8/2024Canaccord Genuity GroupLower TargetHold ➝ Hold$46.00 ➝ $43.00Low
5/8/2024Piper SandlerBoost TargetNeutral ➝ Neutral$33.00 ➝ $40.00Low
5/8/2024MizuhoBoost TargetBuy ➝ Buy$53.00 ➝ $55.00Low
4/11/2024MizuhoBoost TargetBuy ➝ Buy$45.00 ➝ $53.00Low
4/8/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$32.00 ➝ $46.00Low
4/4/2024William BlairUpgradeMarket Perform ➝ OutperformLow
4/4/2024Needham & Company LLCReiterated RatingHoldLow
4/1/2024Stifel NicolausReiterated RatingBuy ➝ Buy$50.00Low
3/11/2024Stifel NicolausUpgradeHold ➝ Buy$30.00 ➝ $50.00Low
2/28/2024MizuhoLower TargetBuy ➝ Buy$50.00 ➝ $45.00Low
2/27/2024Piper SandlerLower TargetNeutral ➝ Neutral$40.00 ➝ $33.00Low
12/5/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
12/4/2023Morgan StanleyInitiated CoverageEqual Weight$35.00Low
11/2/2023Needham & Company LLCLower TargetBuy ➝ Buy$52.00 ➝ $49.00Low
11/2/2023Piper SandlerLower TargetNeutral ➝ Neutral$45.00 ➝ $40.00N/A
9/22/2023Stifel NicolausLower TargetHold ➝ Hold$45.00 ➝ $40.00Low
9/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$54.00 ➝ $52.00Low
9/15/2023Piper SandlerLower TargetNeutral ➝ Neutral$50.00 ➝ $45.00Low
9/15/2023BenchmarkDowngradeBuy ➝ HoldLow
9/13/2023Stifel NicolausReiterated RatingHold ➝ Hold$45.00Low
9/13/2023MizuhoReiterated RatingBuy ➝ Buy$65.00Low
8/21/2023Stifel NicolausLower TargetHold ➝ Hold$50.00 ➝ $45.00Low
8/14/2023StephensReiterated RatingOverweight ➝ Overweight$57.00Low
8/4/2023StephensLower TargetOverweight ➝ Overweight$71.00 ➝ $57.00Low
8/3/2023Piper SandlerLower TargetNeutral ➝ Neutral$65.00 ➝ $50.00Low
8/3/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$77.00 ➝ $48.00Low
8/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$75.00 ➝ $58.00Low
8/3/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$77.00 ➝ $48.00Low
7/17/2023MizuhoLower Target$85.00 ➝ $65.00Low
6/12/2023Stifel NicolausLower Target$60.00 ➝ $55.00Low
6/7/2023William BlairDowngradeOutperform ➝ Market PerformLow
5/4/2023Needham & Company LLCBoost Target$78.00 ➝ $84.00Low
4/17/2023Piper SandlerInitiated CoverageNeutral$65.00Low
2/22/2023StephensReiterated RatingOverweight$85.00Low
2/22/2023Needham & Company LLCLower TargetBuy$83.00 ➝ $78.00Low
2/6/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
2/1/2023BenchmarkLower TargetBuy$78.00 ➝ $75.00Low
1/30/2023Canaccord Genuity GroupBoost TargetBuy$79.00 ➝ $80.00Low
1/20/2023Canaccord Genuity GroupBoost TargetBuy$76.00 ➝ $79.00Low
12/28/2022BTIG ResearchLower TargetBuy$80.00 ➝ $67.00Low
12/28/2022StephensLower TargetOverweight$91.00 ➝ $85.00Low
12/7/2022Stifel NicolausInitiated CoverageHold$60.00Low
11/30/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$88.00 ➝ $79.00Low
11/7/2022SidotiUpgradeNeutral ➝ BuyLow
11/3/2022Needham & Company LLCLower TargetBuy$110.00 ➝ $83.00Low
11/3/2022BTIG ResearchLower TargetBuy$103.00 ➝ $80.00Low
10/14/2022Canaccord Genuity GroupLower TargetBuy$97.00 ➝ $88.00Low
10/14/2022UBS GroupLower TargetBuy ➝ Buy$97.00 ➝ $88.00Low
10/13/2022StephensInitiated CoverageOverweight$91.00Low
10/12/2022MizuhoInitiated CoverageBuy$85.00Low
8/11/2022Canaccord Genuity GroupBoost Target$89.00 ➝ $97.00Low
8/11/2022Jefferies Financial GroupLower Target$165.00 ➝ $125.00Low
8/11/2022BTIG ResearchBoost Target$98.00 ➝ $103.00Low
8/11/2022Needham & Company LLCBoost TargetBuy$87.00 ➝ $110.00Low
8/11/2022BenchmarkBoost TargetBuy$97.00 ➝ $117.00Low
5/3/2022Needham & Company LLCReiterated RatingBuy$87.00Low
4/26/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$81.00 ➝ $89.00Low
4/23/2022BTIG ResearchReiterated RatingBuy$98.00High
4/8/2022Needham & Company LLCInitiated CoverageBuy$87.00High
3/28/2022BenchmarkUpgradeHold ➝ Buy$97.00High
3/18/2022BTIG ResearchUpgradeNeutral ➝ Buy$98.00High
2/25/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$150.00 ➝ $97.00High
7/8/2021OppenheimerInitiated CoverageMarket Perform$150.00Low
2/8/2021BTIG ResearchReiterated RatingHoldHigh
1/19/2021BenchmarkDowngradeBuy ➝ HoldLow
10/26/2020SidotiDowngradeBuy ➝ NeutralHigh
8/31/2020SidotiUpgradeNeutral ➝ Buy$58.00High
8/28/2020BTIG ResearchReiterated RatingHoldLow
8/6/2020BenchmarkBoost TargetBuy$50.00 ➝ $66.00High
7/8/2020StephensBoost TargetOverweight$45.00 ➝ $63.00Low
7/6/2020BTIG ResearchReiterated RatingHoldLow
7/6/2020SidotiDowngradeBuy ➝ Neutral$58.00High
6/24/2020BTIG ResearchReiterated RatingBuy ➝ NeutralHigh
6/15/2020Jefferies Financial GroupInitiated CoverageBuy$55.00High
5/6/2020BTIG ResearchReiterated RatingBuy$41.00Medium
3/23/2020StephensLower TargetOverweight$56.00 ➝ $37.00Medium
3/10/2020BTIG ResearchReiterated RatingBuy$46.00High
1/2/2020StephensReiterated RatingBuy$56.00Low
12/4/2019BTIG ResearchInitiated CoverageBuy$46.00High
(Data available from 5/22/2019 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/22/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/21/2024
  • 14 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/22/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/21/2024
  • 11 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/21/2024

Current Sentiment

  • 11 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
STAAR Surgical logo
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Read More

Today's Range

Now: $42.51
Low: $41.78
High: $43.08

50 Day Range

MA: $43.55
Low: $36.00
High: $52.25

52 Week Range

Now: $42.51
Low: $26.66
High: $65.06

Volume

381,159 shs

Average Volume

526,328 shs

Market Capitalization

$2.09 billion

P/E Ratio

137.13

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of STAAR Surgical?

The following sell-side analysts have issued reports on STAAR Surgical in the last twelve months: Benchmark Co., Canaccord Genuity Group Inc., Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Stephens, Stifel Nicolaus, StockNews.com, and William Blair.
View the latest analyst ratings for STAA.

What is the current price target for STAAR Surgical?

8 Wall Street analysts have set twelve-month price targets for STAAR Surgical in the last year. Their average twelve-month price target is $47.13, suggesting a possible upside of 10.9%. Stephens has the highest price target set, predicting STAA will reach $57.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $35.00 for STAAR Surgical in the next year.
View the latest price targets for STAA.

What is the current consensus analyst rating for STAAR Surgical?

STAAR Surgical currently has 6 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in STAA, but not buy more shares or sell existing shares.
View the latest ratings for STAA.

What other companies compete with STAAR Surgical?

Other companies that are similar to STAAR Surgical include RxSight, Warby Parker, National Vision, Bausch + Lomb and Zai Lab. Learn More about companies similar to STAAR Surgical.

How do I contact STAAR Surgical's investor relations team?

STAAR Surgical's physical mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier's listed phone number is (626) 303-7902 and its investor relations email address is [email protected]. The official website for STAAR Surgical is www.staar.com. Learn More about contacing STAAR Surgical investor relations.